KUOW54m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.
btimesonline4h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
STAT7h
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...